RecruitingNCT07584265

Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations

Engagement Study to Establish a Clinical Baseline for Adult Participants With Factor V Leiden or Prothrombin G20210A Mutation and Familiarise Them With the Clinical Trials Unit Environment for Future Clinical Trial Participation.


Sponsor

Richmond Research Institute

Enrollment

100 participants

Start Date

Apr 21, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This study will enrol individuals who have, or may have, Factor V Leiden or Prothrombin G20210A mutations, which are genetic changes linked to an increased risk of blood clots. Targeted genetic testing will be carried out, where appropriate, to confirm whether participants have one of these genetic variants. Those with a confirmed result will attend a site visit for basic health checks, including blood pressure measurements, ECG, and blood tests, to establish a baseline of their general health and help identify suitability for future related clinical trials. The study also provides participants with the opportunity to learn more about clinical research and become familiar with the clinical trial unit and team. Participation lasts approximately 10 weeks and includes 1-2 site visits and a follow-up telephone call.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Male or female participants aged ≥ 18 years at the date of signing the Participant Information Sheet/Informed Consent Form (PIS/ICF).
  • Ability to provide written, personally signed, and dated informed consent in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines E6 (R3) (2025) and applicable regulations, before any study-specific procedures are performed.
  • Confirmed or suspected diagnosis of FVL or Prothrombin G20210A mutation via targeted genetic testing.

Exclusion Criteria2

  • Unwilling or unable to comply with the protocol-defined study assessments.
  • Any other significant disease or disorder that, in the opinion of the Principal Investigator (PI) or Sponsor, may either place the participant at risk from participation, or influence the clinical baseline.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Richmond Pharmacology Limited

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07584265


Related Trials